

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lenting et al.

Application No.: 09/831,679

Filed: May 10, 2001

For: FACTOR VIII POLYPEPTIDE HAVING
FACTOR VIII: C ACTIVITY

)

Assistant Commissioner for Patents Washington, D.C. 20231

Group Art Unit: 1653

Examiner: Samuel W. Liu

RECEIVED

MAR 1 0 2003

RESPONSE TO RESTRICTION REQUIREMENT

In response to the office Action mailed October 3, 2002, please enter and consider the following.

REMARKS

Claims 1-19 are pending in the present application. The Examiner has requested that Applicants elect one group under 35 U.S.C. §121 as follows:

Group I – Claims 1-5 and 15-17, drawn to an isolated polypeptide and a preparation comprising the polypeptide, are classified in class 530, subclass 350 and class 514, subclass 2, for example.

Group II - Claims 6-13 and 14, drawn to a polynucleotide, an expression vector comprising the polynucleotide, a host cell for the expression of the polynucleotide and a process of synthesizing the polypeptide encoded by the polynucleotide, are classified in class 536, subclass 23.1, class 435, subclass 69.1.320.1, 252.3 and 325+, for example.

Group III – Claims 18 and 19, drawn to a method for treating a coagulation disorder, are classified in class 514, subclass 2, class 530, subclass 350, class 435, subclass 7.1, class 604, subclass 19, for example.

Applicants hereby elect to prosecute Group I without traverse

Applicants request that the application now be examined on the merits.

If the Examiner believes a telephone conference would expedite prosecution of this application,

please telephone the undersigned at (805) 372-3553.

Respectfully submitted,

Michael F. Fedrick

Registration No 36,799

Facsimile: (805) 372-3562

Baxter Healthcare Corporation Post Office Box 15210 Irvine, CA 92623-5210

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this document (along with any referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Lubel No. EV201037634US, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on Marfch 3, 2003.

RECEIVED

MAR 1 0 2003

TECH CENTER 1600/2900

P. 04